Cedarburg Hauser bolsters API ability; Recipharm wins Japanese nod;

> Cedarburg Hauser expects to increase its API production by as much as 25% thanks to a facility upgrade. News

> Recipharm won Japanese approval to manufacture an opioid for local drugmaker Kyowa Hakko Kirin. Story

Suggested Articles

Major CRO player Pharmaceutical Product Development is set to go back on the public markets after announcing its IPO plans.

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Independent site management organization Panthera Biopartners has kick-started its first clinical trial in the U.K.